Periodic Reporting for period 1 - HDM-FUN (Host directed medicine in invasive fungal infection)
Période du rapport: 2020-01-01 au 2021-06-30
To this aim two clinical trials of host-directed medicine approaches will be performed: an immunotherapy trial with interferon gamma (IFNγ in patients with candidemia and a prospective observational trial in patients with influenza to identify patients at risk for aspergillosis that might benefit from antifungal prophylaxis.
Besides, we have started to communicate project activities and also raising awareness about novel treatments in fungi infections in the scientific community and general public.
HDM-FUN will contribute to (i) creating societal impact by changing clinical practice to better control infectious diseases and reduce their burden, thereby ensuring health and well-being for all, at every stage of life; (ii) reducing antimicrobial resistance; and (iii) developing HPF-based targeted treatments and preventive measures, HPF-biomarker based diagnostics and novel standards with respect to clinical trials and protocols.